Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Paris – page 97

2 621 clinical trials in Paris, France across 36 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Paris at a glance
2 621
clinical trials
  • Research sites36
Type of trial
Recruitment status
Quick filters

2 621 trials in Paris

Open in trial search

Non-small cell lung cancer

Not yet recruiting

Phase 3 Study of Taletrectinib as Adjuvant Therapy in Patients with Completely Resected ROS1‑Positive Stage IB‑IIIA Non‑Small Cell Lung Cancer

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Taletrectinib
  • Sponsor:Nuvation Bio Inc.

Alcoholism

Not yet recruiting

Effect of Hydroxocobalamin Acetate, Thiamine Hydrochloride, and Pyridoxine Hydrochloride Supplementation on Brain Injury in Outpatients with Alcohol Use Disorder

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Pyridoxine Hydrochloride
  • Sponsor:Inserm

Systemic scleroderma

Not yet recruiting

Safety and Efficacy of MTX-474 in Adults with Diffuse Cutaneous Systemic Sclerosis (dcSSc) – A Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Glucose Monohydrate
  • Sponsor:Mediar Therapeutics Inc.

Dry age-related macular degeneration+1

Not yet recruiting

Safety, tolerability and exploratory efficacy of PST-611 in patients with geographic atrophy secondary to age-related macular degeneration

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Sponsor:PulseSight Therapeutics

IPEX syndrome

Not yet recruiting

Safety and Efficacy Study of FOXP3‑T4 and Aldesleukin in Patients with IPEX Syndrome

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Aldesleukin
  • Sponsor:Assistance Publique Hopitaux De Paris

Osteogenesis imperfecta

Not yet recruiting

Phase 2 Study of AGA2115 in Adults with Osteogenesis Imperfecta (COL1A1/COL1A2 Variants) Evaluating Bone Density

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Angitia Inc. Ltd.

Narcolepsy

Not yet recruiting

A Randomized Double‑Blind Placebo‑Controlled Study of TAK‑360 in Adults with Narcolepsy with Cataplexy (Type 1)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Takeda Development Center Americas Inc.

Systemic scleroderma+1

Not yet recruiting

Study of CC-97540 (CD19‑Targeted NEX‑T CAR T) versus drug combination in adults with active systemic sclerosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:CC-97540
  • Sponsor:Celgene Corp.

Interstitial lung disease+2

Not yet recruiting

Long‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Admilparant
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Pancreatic neuroendocrine tumour

Not yet recruiting

Randomized phase III adjuvant capecitabine plus temozolomide versus surveillance in patients with resected stage I‑III pancreatic neuroendocrine tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Institut Gustave Roussy

Acute lymphocytic leukaemia

Not yet recruiting

Long‑term safety study of S68587 (allogeneic CD19 CAR T‑cells with TRAC and CD52 disruption) in patients with advanced lymphoid leukemia

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Granulomatosis with polyangiitis+1

Not yet recruiting

Rituximab versus clinic‑biological monitoring for ANCA reactivation in patients with GPA or MPA (with prednisolone)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:Assistance Publique Hopitaux De Paris

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Paris

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on head and neck squamous cell carcinoma and endometrial cancer, evaluating innovative treatment combinations and survival outcomes.

  • Advanced cancer therapies
  • Combination treatments
  • Survival outcome assessment
02 Metabolic Disorders

Clinical investigations targeting Type 1 Diabetes and obesity, with novel therapeutic approaches using tirzepatide for improved glycemic control.

  • Diabetes management
  • Weight control
  • Metabolic health
03 Infectious Diseases

Innovative vaccine trials for COVID-19, influenza, and cytomegalovirus, exploring both intranasal and injectable delivery methods.

  • Vaccine development
  • Immunogenicity studies
  • Prevention strategies
04 Neurological Conditions

Advanced research in multiple sclerosis and Alzheimer's disease, utilizing cutting-edge imaging techniques to study neuroinflammation and synaptic density.

  • Brain imaging
  • Neurodegenerative diseases
  • Disease progression
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.